Cancer Biology Program

癌症生物学项目

• 批准号: 10493586
• 负责人: KRISTI L NEUFELD
• 金额: $ 2.93万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-11 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493586
• 关键词: Affect; Animal Model; Basic Science; Behavior; Biochemical; Biochemistry; Biological; Biological Markers; Bladder; Breast; Cancer Biology; Cancer Center; Cancer Center Support Grant; Catchment Area; Cell Proliferation; Cell Survival; Cells; Cellular biology; Cessation of life; Child; Clinical; Collaborations; Communities; DNA Repair; Development; Discipline; Disease; Distant; Fostering; Funding; Genes; Genetic; Genotoxic Stress; Goals; Hematologic Neoplasms; Hematopoietic System; Institutes; Institution; International; Invaded; Journals; Kansas; Kidney; Leadership; Liver; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Medical Research; Medical center; Methods; Molecular; NCI-Designated Cancer Center; Neoplasm Metastasis; Normal Cell; Organ; Outcome; Pancreas; Paper; Pathway interactions; Peer Review; Prevention strategy; Process; Publications; Publishing; Quality of life; Regulation; Research; Research Personnel; Signal Pathway; Signal Transduction; Strategic Planning; Therapeutic; Tissues; Tobacco-Related Carcinoma; Translating; Translational Research; Tumor Cell Biology; Tumor Stem Cells; United States National Institutes of Health; Universities; base; bench to bedside; biochemical model; cancer cell; cancer prevention; cancer therapy; cancer type; cell behavior; cell growth; cellular targeting; clinical development; cohesion; diagnostic strategy; experience; gastrointestinal; improved; interdisciplinary collaboration; meetings; member; multidisciplinary; neoplastic cell; novel; novel strategies; preclinical development; programs; recruit; response; stem cell biology; stem cell therapy; symposium; therapy development; therapy resistant; translational research program; tumor; tumor growth; tumor initiation; tumor microenvironment; tumor progression

CANCER BIOLOGY: ABSTRACT The Cancer Biology (CB) program represents basic science initiatives of The University of Kansas Cancer Center (KUCC), unified by member utilization of molecular, biochemical, and model organism and cell-based approaches to study the aberrant behavior of cancer cells. The CB scientific goal is to support KUCC’s strategic plan by discerning the molecular mechanisms that define normal and neoplastic cell growth to identify and characterize cells, molecules, pathways, and processes that are involved in tumor growth and progression, which can serve as useful biomarkers or as new cellular targets for cancer prevention and therapeutics, particularly in tumors important to the KUCC’s catchment area. To accomplish this, CB aims to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside. CB has 46 full and 14 associate members representing four campuses: the University of Kansas Medical Center (KUMC) (67%), University of Kansas – Lawrence (KU-L) (10%), Children’s Mercy (CM) (5%), and Stowers Institute for Medical Research (Stowers) (18%). In 2020, CB garnered over $9M in cancer-related, peer-reviewed funding of which $1.2M was from NCI and $6.9M was from other institutes at NIH. From 2016- 2020, members published 880 cancer-relevant, peer-reviewed papers. Of these publications, 13% were in high-impact journals (JIF >10) and the average impact factor for all 880 publications is 6.1. Since renewing the CCSG in 2017, CB program cohesion and integration have increased, with 21% of the publications during the funding cycle resulting from inter-programmatic interactions (up from 20% in 2016) and 29% from intra- programmatic interactions (up from 21% in 2016). CB members are well-integrated into the national and international scientific community as evident by over half of the publications (51%) including authors from other institutions and 23% including authors from other NCI-designated cancer centers. CB is jointly led by Kristi Neufeld (KU-L), Linheng Li (Stowers), Sufi Thomas (KUMC), and Tomoo Iwakuma (CM), who bring complementary scientific expertise in cell biology, stem cell biology, biochemistry, translational research, leadership experience, and diverse institutional representation. Shrikant Anant is Associate Director for Basic Science. CB leadership employs a variety of mechanisms to foster intra- and inter-programmatic collaborations, including research retreats, seminars, research symposia, and targeted pilot funding. CB has taken advantage of historical institutional strengths in catchment area priorities, GI, and hematologic cancers, with recruitment strengthening our research on breast and tobacco-related cancers. CB members have expertise that can be organized into four discipline-based themes: 1) cancer metastasis and tumor microenvironment; 2) DNA damage/repair and regulation; 3) stem cell biology; and 4) cell signaling pathways.

癌症生物学：摘要 癌症生物学 (CB) 项目代表了堪萨斯大学癌症中心的基础科学举措 中心（KUCC），由成员统一利用分子、生物化学、模式生物和细胞基础 研究癌细胞异常行为的方法 CB 的科学目标是支持 KUCC 的研究。 通过辨别定义正常和肿瘤细胞生长的分子机制来确定战略计划 并表征参与肿瘤生长和进展的细胞、分子、途径和过程， 它可以作为有用的生物标志物或作为癌症预防和治疗的新细胞靶标， 特别是对于 KUCC 服务区域重要的肿瘤，CB 旨在促进这一目标。 促进可从实验室转化为临床的基本发现的合作。 CB 有 46 名正式会员和 14 名准会员，代表四个校区： 堪萨斯大学医学院 中心 (KUMC) (67%)、堪萨斯大学劳伦斯分校 (KU-L) (10%)、儿童慈善中心 (CM) (5%) 和 斯托尔斯医学研究所 (Stowers) (18%) 2020 年，CB 在癌症相关领域获得了超过 900 万美元的收入。 2016 年至今，经过同行评审的资金，其中 120 万美元来自 NCI，690 万美元来自 NIH 其他机构。 2020 年，成员发表了 880 篇与癌症相关的同行评审论文，其中 13% 发表在期刊上。 高影响力期刊 (JIF >10)，自更新以来，所有 880 种出版物的平均影响因子为 6.1。 2017年CCSG，CB项目凝聚力和整合度有所提高，期间发表的出版物占21% 项目间互动产生的资金周期（高于 2016 年的 20%）和项目内部互动产生的 29% 计划性互动（高于 2016 年的 21%）。 国际科学界的证据表明，超过一半的出版物（51%）包括来自其他国家的作者 机构和 23% 包括来自其他 NCI 指定癌症中心的作者。 CB 由 Kristi Neufeld (KU-L)、Linheng Li (Stowers)、Sufi Thomas (KUMC) 和 Tomoo Iwakuma 共同领导 （CM），他们带来了细胞生物学、干细胞生物学、生物化学、转化方面的互补科学专业知识 Shrikant Anant 是副主任。 CB 领导层采用多种机制来促进计划内和计划间的发展。 CB 已开展合作，包括研究务虚会、研讨会、研究专题讨论会和有针对性的试点资金。 利用在流域优先事项、胃肠道和血液癌症方面的历史机构优势， 随着招募加强我们对乳腺癌和烟草相关癌症的研究。 专业知识可分为四个基于学科的主题：1）癌症转移和肿瘤 微环境；2) DNA 损伤/修复和调节；3) 干细胞生物学；4) 细胞信号通路。